Last reviewed · How we verify
Lamivudine Oral Solution
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing viral replication by inhibiting the conversion of viral RNA to DNA.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing viral replication by inhibiting the conversion of viral RNA to DNA. Used for HIV-1 infection (in combination antiretroviral therapy), Chronic hepatitis B infection.
At a glance
| Generic name | Lamivudine Oral Solution |
|---|---|
| Also known as | 3TC |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) |
| Target | HIV reverse transcriptase; Hepatitis B virus polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Lamivudine is a cytidine analog that gets phosphorylated intracellularly and incorporated into the growing DNA chain during reverse transcription, causing chain termination. By inhibiting reverse transcriptase, it prevents HIV from converting its RNA genome into DNA that can integrate into the host cell genome. It also has activity against hepatitis B virus through similar mechanisms.
Approved indications
- HIV-1 infection (in combination antiretroviral therapy)
- Chronic hepatitis B infection
Common side effects
- Headache
- Nausea
- Fatigue
- Diarrhea
- Pancreatitis
- Peripheral neuropathy
- Lactic acidosis
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Reducing Vertical Transmission of Hepatitis B in Africa (PHASE3)
- Reverse Transcriptase Inhibitors in AGS (PHASE2)
- Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome (PHASE2)
- Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention (PHASE3)
- Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV (PHASE2)
- Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand (PHASE1, PHASE2)
- IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lamivudine Oral Solution CI brief — competitive landscape report
- Lamivudine Oral Solution updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI